Who has invested in ExeVir Bio?

Fund+, VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures, SRIW are named among the investors backing ExeVir Bio.

ExeVir Bio Funding: $104M Raised, Series A (2023)

ExeVir Bio funding overview

ExeVir Bio is based in Ghent, Belgium. ExeVir Bio has raised $104M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in January 2023. The round record for ExeVir Bio runs through 2023; nothing later has been disclosed. Investors on record include Fund+, VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures, SRIW and 4 others. 10 distinct backers are named across the disclosed rounds.

ExeVir Bio at a glance

Total raised: $104M
Latest round: Series A
Latest round date: January 2023
Headquarters: Ghent, Belgium
Notable investors: Fund+, VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures, SRIW, Noshaq, Vives IUF

Frequently asked about ExeVir Bio funding

How much has ExeVir Bio raised?: ExeVir Bio has raised $104M in total disclosed funding across the rounds on record.
Who has invested in ExeVir Bio?: Fund+, VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures, SRIW are named among the investors backing ExeVir Bio.
What was the latest ExeVir Bio funding round?: The most recent disclosed round is a Series A, announced in January 2023.
Where is ExeVir Bio based?: ExeVir Bio is based in Ghent, Belgium.
When did ExeVir Bio last raise?: The last disclosed ExeVir Bio round closed in January 2023 at Series A.

Round data for ExeVir Bio is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Ghent and backer lists below.

ExeVir Bio Funding: $104M Raised, Series A (2023)

ExeVir Bio funding overview

ExeVir Bio at a glance

Frequently asked about ExeVir Bio funding

Companies related to ExeVir Bio (23)

Browse related funding lists (6)